Endothelial PTBP1 Deletion in Transplanted Cardiac Tissue Limits Cardiac Allograft Vasculopathy

This study identifies endothelial PTBP1 as a critical regulator of cardiac allograft vasculopathy, demonstrating that its deletion preserves mitochondrial function and suppresses fibrotic and immune responses to limit chronic graft injury.

The Gist

The Big Picture: The "Silent Killer" of Heart Transplants

Imagine you get a brand-new heart transplant. The surgery is a success, and you feel great. But years later, a slow, silent problem starts to creep in. The blood vessels inside your new heart begin to clog up and harden, like old pipes filled with rust and sludge. This condition is called Cardiac Allograft Vasculopathy (CAV).

Unlike regular clogged arteries (which happen in everyone as they age), CAV is unique because the body's immune system is slowly attacking the new heart's blood vessels. Currently, doctors have very few tools to stop this. They usually just give patients strong drugs to suppress the whole immune system, which makes them vulnerable to infections and cancer.

This paper discovers a specific "switch" inside the blood vessel cells that drives this clogging process. If you can flip that switch off, you might be able to stop the clogging without needing to shut down the entire immune system.

---

The Main Character: PTBP1 (The "Traffic Controller")

The scientists found a protein called PTBP1. Think of PTBP1 as a traffic controller inside the cells that line your blood vessels (endothelial cells).

• In a healthy heart: This traffic controller keeps things running smoothly. It helps the cells decide which instructions to follow and which to ignore.
• In a failing transplant: When the heart is under stress (from the immune system or lack of oxygen), this traffic controller goes haywire. It starts forcing the cells to follow a "bad instruction manual."

The Analogy: Imagine a factory worker (the cell) who is supposed to keep the machinery running efficiently (using oxygen to make energy). The haywire traffic controller (PTBP1) grabs the worker's radio and shouts, "Stop using the efficient electric motor! Switch to the dirty, smoky backup generator!"

When the cell switches to this "dirty generator," it starts producing toxic waste and sending out distress signals. These distress signals scream to the immune system, "We are under attack! Send the troops!" This causes inflammation, scarring, and eventually, the blood vessels get clogged.

How They Found It: The "Super-Microscope"

The researchers didn't just guess; they looked at real human hearts. They used a high-tech method called inCITE-seq.

• The Analogy: Imagine you have a giant library of books (cells) from different heart patients. Usually, you can only read the text (RNA) to see what the cells are doing. But this new technology is like a super-microscope that lets you read the text and see the physical tools (proteins) the workers are holding at the same time.
• The Discovery: They looked at hearts from patients who had just had a transplant (healthy) versus hearts that were failing years later (CAV). They saw that in the failing hearts, the "traffic controllers" (PTBP1) were screamingly loud and everywhere. The more PTBP1 there was, the worse the heart function was.

The Experiment: Turning Off the Switch

To prove that PTBP1 was actually causing the problem, they tested it on mice.

1. The Setup: They took mice hearts and transplanted them into other mice. In some mice, they genetically "turned off" the PTBP1 switch in the blood vessel cells before the transplant. In others, the switch was left on (the control group).
2. The Result:
   • With the switch ON: The blood vessels clogged up, the heart got scarred, and the immune system went into overdrive.
   • With the switch OFF: The blood vessels stayed clean! The heart didn't scar as much, and the immune system stayed calm.
   • The Magic: The protection offered by turning off this one switch was just as good as giving the mice a massive dose of drugs to wipe out their T-cells and NK cells (the immune soldiers). But unlike the drugs, turning off the switch didn't hurt the rest of the body's immune system.

The Mechanism: Why Does Turning It Off Help?

Why did turning off PTBP1 save the heart? It comes down to energy.

• The Problem: When PTBP1 is active, it forces the blood vessel cells to stop using their clean, efficient energy source (Oxidative Phosphorylation) and switch to a messy, inefficient one. This mess causes the cell's "power plants" (mitochondria) to break apart.
• The Consequence: When the power plants break, they leak "danger signals" (like mitochondrial DNA) into the cell. The cell thinks, "Oh no, we've been invaded!" and sounds the alarm (Interferon signaling), calling the immune system to attack.
• The Solution: When they turned off PTBP1, the cells kept their power plants intact and running on clean energy. No broken power plants meant no danger signals, which meant the immune system stayed calm and didn't attack the new heart.

The Bottom Line: A New Way to Treat Transplants

This paper suggests a brilliant new strategy for heart transplant patients:

Instead of trying to shut down the entire immune system (which is like turning off the lights in the whole house just to stop one bug), we can target PTBP1.

By developing a drug that specifically turns off this "traffic controller" in the blood vessels of the new heart, doctors might be able to:

1. Stop the blood vessels from clogging up.
2. Keep the heart healthy for much longer.
3. Crucially: Allow patients to take less immunosuppressive drugs, keeping them safer from infections and cancer.

In short: The scientists found the specific "glitch" in the heart's wiring that causes rejection. They showed that fixing just that one glitch can save the whole heart, offering hope for a future where heart transplants last a lifetime without constant heavy medication.

Technical Summary

1. Problem Statement

Cardiac Allograft Vasculopathy (CAV) is the leading cause of late graft failure and mortality in heart transplant recipients. Unlike acute rejection, CAV is characterized by progressive, diffuse intimal proliferation within epicardial and intramyocardial vessels, driven by chronic immune activation and endothelial dysfunction.

• Current Limitations: Existing therapies are limited because prolonged systemic immunosuppression carries high risks of infection and malignancy, yet it often fails to prevent CAV.
• Knowledge Gap: The molecular mechanisms linking endothelial stress (specifically TGF-β signaling and metabolic reprogramming) to chronic vascular remodeling and immune activation in CAV remain poorly defined. Specifically, the role of post-transcriptional regulation by RNA-binding proteins (RBPs) in this context was unknown.

2. Methodology

The study employed a multi-omics approach combining human clinical samples with murine genetic models to bridge translational gaps.

• Human Cohort & inCITE-seq:

  • Samples: Nuclei were isolated from four groups: (1) early post-transplant CAV-negative biopsies, (2) CAV-negative explants with acute cellular rejection (ACR), (3) late-stage CAV-positive explants, and (4) naïve non-transplanted controls.
  • Technique: inCITE-seq (intranuclear Cellular Indexing of Transcriptomes and Epitopes) was used. This single-nucleus multi-omics method simultaneously quantified nuclear RNA transcripts and nuclear protein levels (specifically the splice factor PTBP1) using oligonucleotide-tagged antibodies.
  • Analysis: SNP-based genetic profiling distinguished donor (graft) vs. host nuclei. Pseudobulk analysis and Gene Set Enrichment Analysis (GSEA) were performed to correlate PTBP1 protein levels with transcriptional pathways.

• Murine Model:

  • Model: Heterotopic heart transplantation using a F1 hybrid model (C57BL/6 donor $\to$ F1 C57BL/6 $\times$ BALB/c recipient). This model triggers NK cell and CD4+ T cell-dependent immune activation, recapitulating human CAV.
  • Genetic Manipulation: Donor mice were engineered with endothelial-specific deletion of Ptbp1 (Cdh5(PAC)-CreERT2; Ptbp1$^{f/f}$). Tamoxifen was administered to induce deletion prior to transplantation.
  • Assessment: Grafts were analyzed at 40 days post-transplant for histology (neointimal hyperplasia, fibrosis, hypoxia) and immune profiling.

• Single-Cell Profiling of Murine Grafts:

  • CITE-seq: Performed on dissociated graft cells to simultaneously profile transcriptomes and surface protein expression (102 immune markers) across immune and non-immune compartments.
  • In Vitro Validation: Human Umbilical Vein Endothelial Cells (HUVECs) and murine aortic endothelial cells (mAECs) were subjected to hypoxia (1% O$_2$) to assess mitochondrial morphology (TOM20 staining) and interferon responses.

3. Key Contributions

• Identification of PTBP1 as a Central Regulator: The study identifies PTBP1 (Polypyrimidine Tract-Binding Protein 1) as a critical, elevated nuclear protein in CAV endothelium that links pro-fibrotic stress to mitochondrial dysfunction.
• Mechanistic Link Between Metabolism and Immunity: It establishes that endothelial metabolic reprogramming (specifically the suppression of oxidative phosphorylation) is not just a consequence of stress but a driver of innate immune activation (interferon signaling) and subsequent adaptive immune rejection.
• Therapeutic Strategy: Demonstrates that targeting endothelial-intrinsic post-transcriptional regulation (via PTBP1 deletion) can limit chronic graft injury without requiring systemic depletion of immune cells.

4. Key Results

A. Human Findings (inCITE-seq)

• PTBP1 Elevation: Nuclear PTBP1 protein levels were markedly elevated in endothelial cells of CAV-positive explants compared to CAV-negative biopsies and naïve hearts.
• Clinical Correlation: High endothelial PTBP1 levels strongly correlated with cardiac dysfunction (reduced ejection fraction, elevated pulmonary capillary wedge pressure).
• Transcriptional Signatures: Endothelial cells with high PTBP1 exhibited:
  • Upregulation of TGF-β signaling and Endothelial-to-Mesenchymal Transition (EndoMT) markers.
  • Significant suppression of Oxidative Phosphorylation (OxPhos) and mitochondrial transcripts.
  • Enrichment of Hedgehog and WNT/$\beta$-catenin pathways.

B. Murine Findings (Endothelial Ptbp1 Deletion)

• Protection from CAV: Endothelial-specific deletion of Ptbp1 in donor hearts resulted in a ~53% reduction in CAV incidence and reduced neointimal hyperplasia. This protection was comparable to the effect of depleting CD4+, CD8+, and NK cells simultaneously.
• Preservation of Tissue Integrity: EC-KO grafts showed reduced cardiac atrophy, decreased fibrosis (fibronectin deposition), and attenuated hypoxia (lower HIF-1$\alpha$) compared to Wild Type (WT) grafts.
• Metabolic Rescue:
  • In EC-KO grafts, the suppression of OxPhos genes seen in WT grafts was reversed.
  • Mitochondrial Integrity: Under hypoxic stress, WT endothelial cells exhibited mitochondrial fission and fragmentation. In contrast, PTBP1-KO cells preserved mitochondrial content and structure.
  • Splicing Mechanism: PTBP1 deletion altered the splicing of mitochondrial regulators, specifically Mff (promoting an isoform that reduces fission) and Immt (MICOS complex component), thereby maintaining mitochondrial integrity.

C. Immune Modulation

• No Change in Recruitment: Total immune cell infiltration (CD45+ cells) was unchanged between WT and EC-KO grafts; adhesion molecule expression (ICAM1, VCAM1) was also similar.
• Attenuated Activation: Despite similar cell numbers, EC-KO grafts exhibited a shift toward a regulatory immune phenotype:
  • Reduced activation and maturation of CD4+ and CD8+ T cells.
  • Reduced maturation of NK cells (fewer KLRG1-high mature NK cells, more immature/progenitor states).
  • Downregulation of interferon signaling (Type I and II) across all cell types.
  • Reduced expression of activation markers (CD44, IL2RB) and adhesion molecules (ICAM-1, LFA-1) on effector cells.

5. Significance

• Novel Pathophysiology: The paper redefines CAV pathogenesis by placing endothelial mitochondrial dysfunction as a primary driver of chronic rejection. It suggests that stress-induced PTBP1 accumulation causes metabolic rewiring (glycolysis shift, OxPhos loss), which triggers mitochondrial DNA release and innate interferon signaling, ultimately amplifying adaptive immune rejection.
• Therapeutic Potential: Targeting endothelial PTBP1 offers a graft-intrinsic therapeutic strategy. Unlike systemic immunosuppression, which broadly suppresses the immune system, inhibiting PTBP1 specifically in the graft endothelium can "de-escalate" the local inflammatory environment and preserve mitochondrial health, potentially extending graft survival while minimizing systemic side effects.
• Translational Relevance: The strong concordance between human CAV samples and the murine model validates PTBP1 as a biomarker and a viable drug target for preventing chronic graft failure.

Conclusion: Endothelial PTBP1 acts as a molecular switch that converts pro-fibrotic and hypoxic stress into mitochondrial dysfunction and immune activation. Its deletion breaks this cycle, preserving graft function and limiting vasculopathy.